Reciprocal interactions between human mesenchymal stem cells and γδ T cells or invariant natural killer T cells

Stem Cells

Volumn 27, Issue 3, 2009, Pages 693-702

  Prigione, Ignazia ^a   Benvenuto, Federica ^b   Bocca, Paola ^a   Battistini, Luca ^c   Uccelli, Antonio ^b,d   Pistoia, Vito ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d Advanced Biotechnology Center   (Italy)

Author keywords

Human mesenchymal stem cells; Invariant natural killer T cells; T cell receptor 1 lymphocytes

Indexed keywords

CD3 ANTIGEN; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDOMETACIN; PROSTAGLANDIN E2; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TRANSFORMING GROWTH FACTOR BETA1;

ANTIGEN PRESENTATION; ARTICLE; CELL ACTIVATION; CELL CONTACT; CELL EXPANSION; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MESENCHYMAL STEM CELL; NATURAL KILLER T CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; T GAMMA DELTA CELL; T LYMPHOCYTE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL PROLIFERATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; INDOMETHACIN; INTERFERON-GAMMA; MESENCHYMAL STEM CELLS; NATURAL KILLER T-CELLS; PROSTAGLANDINS E; T-LYMPHOCYTES;

EID: 65249096100     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2008-0687     Document Type: Article

References (55)

1. Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 1970;3:393-103.
2. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006;119:2204-2213.
3. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
4. Porada CD, Zanjani ED, Almeida-Porad G. Adult mesenchymal stem cells: a pluripotent population with multiple applications. Curr Stem Cell Res Ther 2006;1:365-369.
5. Horwitz EM, Prockop DJ, Fitzpatrick LA et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999;5:309-313.
6. Ozawa K, Sato K, Oh I et al. Cell and gene therapy using mesenchymal stem cells (MSCs). J Autoimmun 2008;30:121-127.
7. Krampera M, Cosmi L, Angeli R et al. Role for interferon-γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006;24:386-398.
8. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007;110:3499-3506.
9. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol 2006;36:2566-2573.
10. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8:726-736.
11. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-1441.
12. Koç ON, Gerson SL, Cooper BW et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000;18:307-316.
13. + cells in NOD/SCID mice. Exp Hematol 2002;30:870-878.
14. Le Blanc K, Samuelsson H, Gustafsson B et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007;21:1733-1738.
15. Ball LM, Bernardo ME, Roelofs H et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007;110:2764-2767.
16. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371:1579-1586.
17. Zappia E, Casazza S, Pedemonte E et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005;106:1755-1761.
18. Uccelli A, Frassoni F, Mancardi G. Stem cells for multiple sclerosis: promises and reality. Regen Med 2007;2:7-9.
19. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004;114:1379-1388.
20. Holtmeier W, Kabelitz D. γδ T cells link innate and adaptive immune responses. Chem Immunol Allergy 2005;86:151-183.
21. Zocchi MR, Poggi A. Role of γδ T lymphocytes in tumor defense. Front Biosci 2004;9:2588-2604.
22. Bach JF, Bendelac A, Brenner MB et al. The role of innate immunity in autoimmunity. J Exp Med 2004;200:1527-1531.
23. Battistini L, Caccamo N, Borsellino G et al. Homing and memory patterns of human γδ T cells in physiopathological situations. Microbes Infect 2005;7:510-517.
24. Bonneville M, Scotet E. Human Vy9Vd2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 2006;18:539-546.
25. Yamamura T, Sakuishi K, Illes Z et al. Understanding the behavior of invariant NKT cells in autoimmune diseases. J Neuroimmunol 2007; 191:8-15.
26. Pillai AB, George TI, Dutt S et al. Host NKT cells can prevent graft- versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol 2007;178:6242-6251.
27. Lan F, Zeng D, Higuchi M et al. Host conditioning with total lymph- oid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells. Biol Blood Marrow Transplant 2003;9:355-363.
28. Morris ES, MacDonald KP, Rowe V et al. NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J Clin Invest 2005;115:3093-3103.
29. Kawano T, Cui J, Koezuka Y et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 1997;278:1626-1629.
30. Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu Rev Immunol 2004;22:817-890.
31. O'Brien RL, Roark CL, Jin N et al. γδ T-cell receptors: functional correlations. Immunol Rev 2007;215:77-88.
32. Bukowski JF, Morita CT, Brenner MB. Human γδ T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity 1999;11:57-65.
33. Constant P, Davodeau F, Peyrat MA et al. Stimulation of human γδ T cells by nonpeptidic mycobacterial ligands. Science 1994;264: 267-270.
34. Tanaka Y, Morita CT, Tanaka Y et al. Natural and synthetic non-peptide antigens recognized by human yd T cells. Nature 1995;375:155-158.
35. Morita CT, Beckman EM, Bukowski JF et al. Direct presentation of nonpeptide prenyl pyrophosphate antigens to human yd T cells. Immunity 1995;3:495-507.
36. Corcione A, Benvenuto F, Ferretti E et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006;107:367-372.
37. Cipriani B, Knowles H, Chen L et al. Involvement of classical and novel protein kinase C isoforms in the response of human Vy9Vd2T cells to phosphate antigens. J Immunol 2002;169:5761-5770.
38. Glennie S, Soeiro I, Dyson PJ et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005;105:2821-2827.
39. Benvenuto F, Ferrari S, Gerdoni E et al. Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells 2007;25: 1753-1760.
40. Prigione I, Chiesa S, Taverna P et al. T cell mediated immune responses to Toxoplasma gondii in pregnant women with primary toxoplasmosis. Microbes Infect 2006;8:552-560.
41. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-1822.
42. Haniffa MA, Wang XN, Holtick U et al. Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol 2007;179:1595-1604.
43. Jones S, Horwood N, Cope A et al. The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol 2007;179:2824-2831.
44. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human γδ T cells. Science 2005;309:264-268.
45. Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res 2006;312:2169-2179.
46. Shiozawa Y, Havens AM, Pienta KJ et al. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008;22:941-950.
47. Bocelli-Tyndall C, Barbero A, Candrian C et al. Human articular chondrocytes suppress in vitro proliferation of anti-CD3 activated peripheral blood mononuclear cells. J Cell Physiol 2006;209:732-734.
48. 2. Blood 2008;111:1327-1333.
49. Sotiropoulou PA, Perez SA, Gritzapis AD et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006;24:74-85.
50. Spaggiari GM, Capobianco A, Becchetti S et al. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006;107:1484-1490.
51. Moser B, Brandes M. γδ T cells: an alternative type of professional APC. Trends Immunol 2006;27:112-118.
52. Jiang XX, Zhang Y, Liu B et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005;105:4120-4126.
53. Jung YJ, Ju SY, Yoo ES et al. MSC-DC interactions: MSC inhibit maturation and migration of BM-derived DC. Cytotherapy 2007;9: 451-458.
54. Dazzi F, Horwood NJ. Potential of mesenchymal stem cell therapy. Curr Opin Oncol 2007;19:650-655.
55. Tyndall A, Walker UA, Cope A et al. Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, U.K., 31 October 2005. Arthritis Res Ther 2007; 9:301.